Therapy Areas: Oncology
Celgene meets co-primary endpoint of progression-free survival in phase III IMpassion130 study
12 July 2018 -

United States-based Celgene has met its co-primary endpoint of progression-free survival in the phase III IMpassion130 study, which was sponsored by Roche, it was reported yesterday.

This is the first phase III study to showcase a statistically significant progression-free survival improvement in first-line metastatic or unresectable locally advanced triple negative breast cancer (TNBC), a type of breast cancer with high unmet need.

The study enrolled 902 people who were randomised equally (1:1). Results indicated that the investigational combination of TECENTRIQ (atezolizumab) and ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) compared to ABRAXANE monotherapy, as an initial (first-line) treatment, significantly decreased the risk of disease worsening or death in patients with metastatic or unresectable locally advanced TNBC in the intention-to-treat and PD-L1 positive populations.

Login
Username:

Password: